Nutrition and health

Objectives:
Does vitamin K reduce risk of cardiovascular disease (CVD) events and mortality?

Study design:
This review article included 21 articles with 222,592 participants.

Results and conclusions:
The investigators found dietary phylloquinone (vitamin K1) intake significantly reduced risk of total cardiovascular disease with 8% [pooled HR = 0.92, 95% CI = 0.84 to 0.99, I2 = 0%, 4 studies].
Significant means that there is an association with a 95% confidence.

The investigators found dietary menaquinone (vitamin K2) intake significantly reduced risk of total cardiovascular disease with 30% [pooled HR = 0.70, 95% CI = 0.53 to 0.93, I2 = 32.1%, 2 studies].
Significant because HR of 1 was not found in the 95% CI of 0.53 to 0.93. HR of 1 means no risk/association.

The investigators found no significant association between dietary vitamin K and all-cause mortality, cardiovascular disease mortality or stroke.

The investigators found elevated plasma desphospho-uncarboxylated MGP (dp-ucMGP), a marker of vitamin K deficiency, was associated with an increased risk of 84% [HR = 1.84, 95% CI = 1.48 to 2.28, I2 = 16.8%, 5 studies] for all-cause mortality.

The investigators found elevated plasma desphospho-uncarboxylated MGP (dp-ucMGP), a marker of vitamin K deficiency, was associated with an increased risk of 96% [HR = 1.96, 95% CI = 1.47 to 2.61, I2 = 0%, 2 studies] for cardiovascular disease mortality.

The investigators found no significant association between circulating total osteocalcin and all-cause mortality or total cardiovascular disease.

The investigators concluded higher dietary vitamin K consumption reduces risk of cardiovascular disease and higher plasma dp-ucMGP concentration, but not total circulating osteocalcin, increases risk of all-cause and cardiovascular disease mortality. However, causal relations cannot be established because of limited number of available studies and larger prospective studies and randomized clinical trials are needed to validate these findings.  

Original title:
Association of vitamin K with cardiovascular events and all-cause mortality: a systematic review and meta-analysis by Chen HG, Sheng LT, […], Pan A.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/31119401

Additional information of El Mondo:
Find more information/studies on vitamin K, significantly/review article and cardiovascular disease right here.

100 grams of fresh parsley provide 548 micrograms (548 mcg) of vitamin K1 or 4.5 days.
 

Objectives:
Is there a causal relationship between grape product supplementation and improved lipid profiles in adults?

Study design:
This review article included 48 RCTs.

Results and conclusions:
The investigators found meta-analysis indicated that consumption of grape products significantly reduced the concentration of total cholesterol [MD = -6.196 mg/dL, 95% CI = -9.203 to -3.189], low-density lipoprotein cholesterol (bad cholesterol) [MD = -4.964 mg/dL, 95% CI = -7.594 to -2.334] and triglyceride [MD = -7.641 mg/dL, 95% CI = -12.120 to -3.162].

The investigators found grape product supplementation changed the HDL and LDL in a non-linear fashion based on the dose of polyphenols.

The investigators concluded that grape products have a favorable role in the achievement of a lipid profile target in adults, particularly total cholesterol, low-density lipoprotein cholesterol (bad cholesterol) and triglyceride levels.

Original title:
Effects of grape products on blood lipids: a systematic review and dose-response meta-analysis of randomized controlled trials by Ghaedi E, Moradi S, [...], Mohammadi H.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/31517353

Additional information of El Mondo:
Find more information/studies on fruits, meta-analysis and cholesterol right here.
 

Objectives:
Does green coffee bean extract (GCBE) supplementation reduce blood pressure?

Study design:
This review article included 9 RCTs.

Results and conclusions:
The investigators found a significant reduction in systolic blood pressure (SBP) [WMD = -3.093 mmHg, 95% CI = -3.914 to -2.273, I2 = 0.0%] and diastolic blood pressure (DBP) [WMD = -2.170 mmHg, 95% CI = -2.749 to -1.590, I2 = 46.5%] after green coffee supplementation with low heterogeneity among the studies.

The investigators found in subgroup analysis, a significant reduction in systolic blood pressure and diastolic blood pressure in studies with hypertensive patients, green coffee dosage 400 mg per day and administered for 4 weeks.

The investigators concluded 400 mg coffee bean extract supplementation per day during 4 weeks reduces systolic blood pressure and diastolic blood pressure in hypertensive patients.

Original title:
The effect of green coffee extract supplementation on blood pressure: A systematic review and meta-analysis of randomized controlled trials by Han B, Nazary-Vannani A, […], Kord-Varkaneh H.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/31429515

Additional information of El Mondo:
Find more information/studies on coffee and reducing blood pressure right here.
 

Objectives:
Do dietary intakes or circulating concentration of major dietary antioxidants, like vitamin C, E and beta-carotene reduce risk of total cardiovascular mortality?

Study design:
This review article included a total of 15 prospective cohort studies and 3 prospective evaluations within interventional studies with 320,548 participants and 16,974 deaths from total cardiovascular mortality.

Results and conclusions:
The investigators found compared to the lowest category, the highest category of dietary vitamin C intake significantly reduced risk of total cardiovascular mortality with 21% [relative risk = 0.79, 95% CI = 0.68 to 0.89, I2 = 46%, n = 10].

The investigators found compared to the lowest category, the highest category of circulating concentration of vitamin C significantly reduced risk of total cardiovascular mortality with 40% [relative risk = 0.60, 95% CI = 0.42 to 0.78, I2 = 65%, n = 6].

The investigators found compared to the lowest category, the highest category of circulating concentration of vitamin E (α-tocopherol) significantly reduced risk of total cardiovascular mortality with 18% [relative risk = 0.82, 95% CI = 0.76 to 0.88, I2 = 0%, n = 5].

The investigators found compared to the lowest category, the highest category of circulating concentration of β-carotene significantly reduced risk of total cardiovascular mortality with 32% [relative risks = 0.68, 95% CI = 0.52 to 0.83, I2 = 50%, n = 6].

The investigators found dose-response meta-analyses demonstrated that the circulating biomarkers of antioxidants were more strongly associated with risk of total cardiovascular mortality than dietary intakes.

The investigators concluded that higher dietary vitamin C intakes and higher circulating concentrations of vitamin C, vitamin E and β-carotene are associated with a lower risk of total cardiovascular mortality.

Original title:
Dietary and circulating vitamin C, vitamin E, β-carotene and risk of total cardiovascular mortality: a systematic review and dose-response meta-analysis of prospective observational studies by Jayedi A, Rashidy-Pour A, […], Shab-Bidar S.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/30630552

Additional information of El Mondo:
Find more information/studies on antioxidants, vitamin C, E, β-carotene and cardiovascular diseases right here.

Circulating concentration of vitamin C in blood can be increased by eating foods that are high in vitamin C and/or taking vitamin C supplements.

Objectives:
Dietary polyphenols, including flavonoids, have been the focus of major recent attentions due to their wide content in a variety of foods commonly consumed and the findings from numerous studies showing evidence of an association with positive outcomes on human health. Therefore, this review article has been conducted.

Does dietary intake of flavonoids (e.g., anthocyanins, isoflavones, flavones, flavonols, flavanones, flavan-3-ols) reduce hypertension?

Study design:
This review article included 15 cross-sectional investigations and 7 prospective cohort studies (1 study reported on 3 prospective cohort studies).
5 prospective cohort studies, comprising 200,256 individuals and 45,732 cases of hypertension were included in the quantitative analysis.

All studies included covariates that may have significantly influenced the endpoint outcome (hypertension), such as age, sex (when not analyzed separately), BMI, education, physical activity and smoking status. However, not all studies adjusted for key dietary factors that might influence risk of hypertension, such as sodium and potassium intake.

There was no publication bias.

Results and conclusions:
The investigators found analysis by extreme quantiles of intake of flavonoid showed a non-significant association with decreased risk of hypertension [risk ratio = 0.96, 95% CI = 0.89 to 1.03, I2 = 74%, p = 0.01].
Non-significant because RR of 1 was found in the 95% CI of 0.89 to 1.03. RR of 1 means no risk/association.

The investigators found taking into consideration individual flavonoid subclasses, dietary intake of anthocyanins was associated with 8% reduction in risk of hypertension, when comparing highest vs. lowest exposure [risk ratio = 0.92, 95% CI = 0.88 to 0.97].
Significant because RR of 1 was not found in the 95% CI of 0.88 to 0.97. RR of 1 means no risk/association.

The investigators concluded dietary intakes of anthocyanins reduce risk of hypertension. However, further studies are needed to elucidate the retrieved association between polyphenol consumption and decreased risk of hypertension and to clarify whether individual subclasses, rather than the total content of polyphenols, may exert beneficial effects on blood pressure.

Original title:
Dietary Polyphenol Intake, Blood Pressure, and Hypertension: A Systematic Review and Meta-Analysis of Observational Studies by Godos J, Vitale M, […], Grosso G.

Link:
https://www.mdpi.com/2076-3921/8/6/152/htm

Additional information of El Mondo:
Find more information/studies on flavonoids and cardiovascular diseases right here.

Objectives:
Preventing cardiovascular disease (CVD) is the top priority in public health. Hyperlipidemia and hypertension are key contributors to cardiovascular disease which can be easily modified with dietary and lifestyle interventions. Therefore, this review article has been conducted.

Does cashew consumption reduce blood lipids levels (i.e., triglyceride, total cholesterol, HDL cholesterol (good cholesterol) and LDL cholesterol (bad cholesterol) and blood pressure?

Study design:
This review article included 5 RCTs with 246 participants receiving cashew nut (intervention group) and 235 receiving placebo (placebo group).

There was no publication bias.

Results and conclusions:
The investigators found overall analysis showed a statistically significant reducing effect of cashew nut consumption on triglyceride levels [WMD = -14.39, 95% CI = -27.30 to -1.49, I2 = 82%].
Significant means that there is an association with a 95% confidence.

The investigators found overall analysis showed a statistically significant reducing effect of cashew nut consumption on systolic blood pressure [WMD = -1 mm/Hg, 95% CI = -5.12 to -3.01, I2 = 0%].

The investigators found overall analysis showed a statistically significant reducing effect of cashew nut consumption on diastolic blood pressure [WMD = -4.06 mm/Hg, 95% CI = -1.65 to -0.35, I2 = 0%].

The investigators found, however, no statistically significant changes of other cardiovascular risk markers including total cholesterol [WMD = -1.89, 95% CI = -9.17 to 5.39, p = 0.61], LDL cholesterol [WMD = -5.49, 95% CI = -16.76 to 5.78, p = 0.34] and HDL cholesterol [WMD = -0.67, 95% CI = -2.54 to 1.19, p = 0.48] were observed after cashew nut consumption.
No statistically significant because the calculated p-values of e.g. 0.61 or 0.34 were larger than the p-value of 0.05.

The investigators concluded that cashew consumption improves triglyceride levels as well as systolic and diastolic blood pressure with no significant effects on other cardiometabolic factors (i.e., total cholesterol, HDL cholesterol (good cholesterol) and LDL cholesterol (bad cholesterol)). Further studies are warranted with different calories and dietary compositions.

Original title:
The Effect of Cashew Nut on Cardiovascular Risk Factors and Blood Pressure: A Systematic Review and Meta-analysis (P06-117-19) by Mahboobi S.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6573847/

Additional information of El Mondo:
Find more information/studies on cashew consumption, cholesterol and cardiovascular diseases right here.

Objectives:
Does coenzyme Q10 (CoQ10) supplementation improve biomarkers of inflammation and oxidative stress among patients with coronary artery disease (CAD)?

Study design:
This review article included 13 RCTs.

Given the presence of heterogeneity, random-effects model or fixed-effect model were used to pool standardized mean differences (SMDs) as summary effect sizes.

Results and conclusions:
The investigators found pooled findings for biomarkers of inflammation and oxidative stress demonstrated that coenzyme Q10 supplementation significantly increased superoxide dismutase (SOD) [SMD = 2.63, 95% CI = 1.17 to 4.09, p  0.001, I2 = 94.5%] and catalase (CAT) levels [SMD = 1.00, 95% CI = 0.57 to 1.43, p  0.001, I2 = 24.5%] among patients with coronary artery disease.

The investigators found pooled findings for biomarkers of inflammation and oxidative stress demonstrated that coenzyme Q10 supplementation significantly reduced malondialdehyde (MDA) [SMD = -4.29, 95% CI = -6.72 to -1.86, p = 0.001, I2 = 97.6%] and diene levels [SMD = -2.40, 95% CI = -3.11 to -1.68, p  0.001, I2 = 72.6%] among patients with coronary artery disease.

The investigators found among patients with coronary artery disease no significant effect of coenzyme Q10 supplementation on:
-C-reactive protein (CRP) [SMD = -0.62, 95% CI = -1.31 to 0.08, p = 0.08, I2 = 87.9%];
-tumor necrosis factor alpha (TNF-α) [SMD = 0.22, 95% CI = -1.07 to 1.51, p = 0.73, I2 = 89.7%];
-interleukin-6 (IL-6) [SMD = -1.63, 95% CI = -3.43 to 0.17, p = 0.07, I2 = 95.2%] and;
-glutathione peroxidase (GPx) levels [SMD = 0.14, 95% CI = -0.77 to 1.04, p = 0.76, I2 = 78.7%].
No significant because the calculated p-values were larger than the p-value of 0.05.

The investigators concluded coenzyme Q10 supplementation increases superoxide dismutase and catalase and decreases malondialdehyde and diene levels, but has no affect on C-reactive protein, tumor necrosis factor alpha, interleukin-6 and glutathione peroxidase levels among patients with coronary artery disease.

Original title:
The effects of coenzyme Q10 supplementation on biomarkers of inflammation and oxidative stress in among coronary artery disease: a systematic review and meta-analysis of randomized controlled trials by Jorat MV, Tabrizi R, […], Asemi Z.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/30758695

Additional information of El Mondo:
Find more information/studies on coenzyme Q10 and cardiovascular diseases right here.

Malondialdehyde and diene are biomarkers of oxidative stress. Oxidative stress can arise when human cells cannot adequately destroy the excess of free radicals formed.

Free radicals can be rendered harmless by antioxidants such as vitamins C and E and by antioxidative enzymes such as superoxide dismutase and catalase.

Objectives:
Does kiwifruit improve metabolic health in participants with cardiovascular risk factors, including hypercholesterolemia, hypertension, diabetes type 2 and smokers?

Study design:
This review article included 5 RCTs involving 489 participants.

Results and conclusions:
The investigators found no significant effect of kiwifruit on:
-systolic blood pressure (SBP) [MD = -1.72 mmHg, 95% CI = -4.27 to 0.84];
-diastolic blood pressure (DBP) [MD = -2.35 mmHg, 95% CI = -5.10 to 0.41];
-total cholesterol (TC) [MD = -0.14 mmol/L, 95% CI = -0.71 to 0.43];
-triglyceride (TG) [MD = -0.23 mmol/L, 95% CI = -0.66 to 0.20];
-low-density lipoprotein cholesterol (bad cholesterol or LDL) [MD = -0.41 mmol/L, 95% CI = -0.99 to 0.18];
-high-density lipoprotein cholesterol (good cholesterol or HDL) [MD = 0.15 mmol/L, 95% CI = -0.18 to 0.48];
-fasting plasma glucose (FPG) [MD = -0.08 mmol/L, 95% CI = -0.37 to 0.21];
-homeostasis model assessment of insulin resistance (HOMA-IR) [MD = -0.29, 95% CI = -0.61 to 0.02] and;
-body weight (BW) [MD = 1.08 kg, 95% CI = -4.22 to 2.05].

The investigators found subgroup analysis limiting to studies of whole kiwifruit and duration of intervention of at least 8 weeks again revealed no such effect of kiwifruit on total cholesterol, triglyceride, LDL cholesterol and HDL cholesterol.

The investigators concluded kiwifruit has no effect on metabolic health, as measured by systolic blood pressure, diastolic blood pressure, total cholesterol, triglycerides, LDL cholesterol and HDL cholesterol, fasting plasma glucose, homeostasis model assessment of insulin resistance (HOMA-IR) and body weight in participants with cardiovascular risk factors including hypercholesterolemia, hypertension, diabetes type 2 and smokers. Due to limited evidence and high heterogeneity of the study results, the potential of kiwifruit as a nonpharmaceutical alternative for metabolic health should be further evaluated in well-defined, well-controlled trials with larger sample size and standardized preparation.

Original title:
Effect of kiwifruit on metabolic health in patients with cardiovascular risk factors: a systematic review and meta-analysis by Suksomboon N, Poolsup N and Lin W.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350646/

Additional information of El Mondo:
Find more information/studies on fruit consumption and cardiovascular diseases right here.

Objectives:
Several epidemiological studies have investigated the association between dietary fat intake and cardiovascular disease. However, dietary recommendations based on systematic review and meta-analysis might be more credible. Therefore, this review article has been conducted.

Does dietary fat intake increase cardiovascular disease risk?

Study design:
This review article included 56 cohort studies.
Egger test showed no evidence of significant publication bias.

Results and conclusions:
The investigators found highest versus lowest levels of total dietary fat were not associated with cardiovascular disease risk [RR = 0.97, 95% CI = 0.93-1.01, I2 = 54.0%].
Sensitivity analysis showed that no individual study had an excessive influence on the pooled effect.
In addition, the analysis was repeated stratified according to each covariate. The results were consistent with that observed in meta-regression.

The investigators found highest versus lowest levels of dietary trans fatty acids intake were associated with a 14% increase of the risk of cardiovascular disease [RR = 1.14, 95% CI = 1.08-1.21, I2 = 26.1%].
Sensitivity analysis showed that no individual study had an excessive influence on the pooled effect.

The investigators found dose-response analysis showed the risk of cardiovascular disease significantly increased with 16% [RR = 1.16, 95% CI = 1.07-1.25, p-linearity = 0.033] for an increment of 2% energy/day (2 En%/day) of dietary trans fatty acids intake.

The investigators found highest versus lowest levels of dietary saturated fatty acids intake were not associated with the risk of cardiovascular disease [RR = 0.97, 95% CI = 0.93-1.02, I2 = 56.8%].
Sensitivity analysis showed that no individual study had an excessive influence on the pooled effect
In addition, the analysis was repeated stratified according to each covariate. The results were consistent with that observed in meta-regression.

The investigators found highest versus lowest levels of dietary monounsaturated fatty acids intake were not associated with the risk of cardiovascular disease [RR = 0.97, 95% CI = 0.93-1.01, I2 = 50.3%].
Sensitivity analysis showed that no individual study had an excessive influence on the pooled effect.
In addition, the analysis was repeated stratified according to each covariate. The results were consistent with that observed in meta-regression.

The investigators found highest versus lowest levels of dietary polyunsaturated fatty acids intake were not associated with the risk of cardiovascular disease [RR = 0.97, 95% CI = 0.93-1.004, I2 = 55.8%].
Sensitivity analysis showed that no individual study had an excessive influence on the pooled effect.
In addition, the analysis was repeated stratified according to each covariate. The results were consistent with that observed in meta-regression.

The investigators found in studies that has been followed up more than 10 years, that dietary polyunsaturated fatty acids intake significantly reduced cardiovascular disease risk with 5% [RR = 0.95, 95% CI = 0.91-0.99, I2 = 62.4%].

The investigators concluded there is a cardio-protective effect of dietary polyunsaturated fatty acids intake in studies that has been followed up more than 10 years. While, an increment of 2% energy/day (2 En%/day) of dietary trans fatty acids intake increases risk of cardiovascular disease.

Original title:
Dietary total fat, fatty acids intake, and risk of cardiovascular disease: a dose-response meta-analysis of cohort studies by Zhu Y, Bo Y and Liu Y.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451787/

Additional information of El Mondo:
Find more information/studies on fat consumption and cardiovascular diseases right here.

Objectives:
Several studies have been conducted on the effects of peanut consumption on cardiovascular diseases (CVD) risk factors. However, the findings are conflicting and appear inconsistent. Therefore, this review article has been conducted.

Does peanut consumption reduce cardiovascular disease risk?

Study design:
This review article included 13 RCTs.

Results and conclusions:
The investigators found peanuts consumption had no significant effect on:
-weight [WMD = -0.11 kg, p = 0.773];
-waist circumference [WMD = -1.41 cm, p = 0.139];
-body mass index [WMD = -0.14 kg/m², p = 0.428];

-systolic and diastolic blood pressure [WMD = -0.09 mmHg, p = 0.939 and WMD = 0.60 mmHg, p = 0.652, respectively];
-low-density lipoprotein (LDL or bad) cholesterol [WMD = -3.31 mg/dL, p = 0.472];
-triglyceride [WMD = -7.59 mg/dL, p = 0.180];
-total cholesterol [WMD = 3.15 mg/dL, p = 0.171];
-fasting blood sugar [WMD = 0.57 mg/dL, p = 0.604] and;
-serum insulin [WMD = -0.40, p = 0.582].

The investigators found peanuts consumption had a positive significant effect on high-density lipoprotein (HDL or good) cholesterol [WMD = 2.72 mg/dL, p = 0.001].
Significant because the calculated p-value of 0.001 was smaller than the p-value of 0.05.

The investigators found peanut consumption had a positive significant effect on HDL cholesterol, especially at the type of peanut oil, high-oleic peanut and peanut sprout and in healthy subjects and for consumption more than 12 weeks, while had no significant effect on other cardiovascular diseases risk factors.

The investigators concluded both high-oleic peanut and peanut sprout consumption during at least 12 weeks increases HDL cholesterol (good cholesterol) in healthy subjects.

Original title:
Peanut and cardiovascular disease risk factors: A systematic review and meta-analysis by Jafari Azad B, Daneshzad E and Azadbakht L.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/30638042

Additional information of El Mondo:
Find more information/studies on nut consumption, cholesterol and cardiovascular diseases right here.

Objectives:
What is the relationship between serum, dietary and urinary potassium and the risk of type 2 diabetes mellitus (T2DM)?  

Study design:
This review article included 8 prospective cohort studies involved 5,053 type 2 diabetes mellitus cases among 119,993 individuals.
The follow-up durations were from 5 to 18.1 years with a baseline age range from 18 to 95 years.
Serum potassium was measured using the ion-selective electrode method. Dietary potassium was estimated from food frequency questionnaire (FFQ). Urinary potassium samples were analyzed by potentiometric methods.
Most of the included studies provided risk estimates adjusted for age, sex, race, BMI and family history of diabetes.

Results and conclusions:
The investigators found in 5 studies involving 28,944 individuals and 3,849 type 2 diabetes mellitus cases, a non-significantly reduced risk of 21% [summary RR = 0.79, 95% CI = 0.60-1.04, I2 = 76.7%] for type 2 diabetes mellitus, when comparing the highest versus lowest serum potassium levels.
However, the sensitivity analysis did show a significant inverse association between serum potassium and type 2 diabetes mellitus risk [RR = 0.63, 95% CI = 0.52-0.73, I2 = 0%].

The investigators found in random dose-response meta-regression analysis a significantly reduced risk of 17% for type 2 diabetes mellitus [RR = 0.83, 95% CI = 0.73-0.95] per 1 mmol/L increase in serum potassium.

The investigators found in 6 studies involving 112,125 individuals and 4,573 type 2 diabetes mellitus cases, a non-significantly reduced risk of 7% [RR = 0.93, 95% CI = 0.81-1.06, I2 = 0.0%, p = 0.52] for type 2 diabetes mellitus, when comparing the highest versus lowest dietary potassium intake.
The sensitivity analysis did not significantly alter the association between dietary potassium and type 2 diabetes mellitus risk.

The investigators found there was no significant dose-response relationship between dietary potassium and type 2 diabetes mellitus risk [RR for every 1000mg increase dietary potassium per day = 1.00, 95% CI = 0.96-1.05].

The investigators found in 3 studies involving 4,376 individuals and 455 type 2 diabetes mellitus cases, a non-significantly reduced risk of 17% [RR = 0.83, 95% CI = 0.39-1.75, I2 = 73.9%, p = 0.02] for type 2 diabetes mellitus, when comparing the highest versus lowest urinary potassium levels.

The investigators found there was no significant dose-response relationship between urinary potassium levels and type 2 diabetes mellitus risk [RR for 10 mmol increase in urinary potassium per 24 hours = 1.00, 95% CI = 0.95-1.05].

The investigators concluded that serum potassium levels are linearly associated with the risk of type 2 diabetes mellitus, with each 1 mmol/L increase in serum potassium lowering the risk by 17%. However, neither dietary potassium nor urinary potassium shows any association with the risk of type 2 diabetes mellitus.

Original title:
Potassium measurements and risk of type 2 diabetes: a dose-response meta-analysis of prospective cohort studies by Peng Y, Zhong GC, […], Yang G.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725047/

Additional information of El Mondo:
Find more information/studies on type 2 diabetes and potassium right here.
 

Objectives:
Over the last 7 years there has been intense debate about the advice to reduce saturated fat and increase polyunsaturated fat to reduce cardiovascular (CVD) risk. Therefore, this review article (meta-analysis) has been conducted.

Does replacement of saturated fat with carbohydrate, polyunsaturated fatty acid (PUFA) or monounsaturated fatty acid (MUFA) reduce cardiovascular risk?

Study design:
This review article included cohort studies and intervention studies.

Results and conclusions:
The investigators found replacement of saturated fat with any carbohydrate, polyunsaturated fatty acid (PUFA) and monounsaturated fatty acid (MUFA) is associated with lower mortality with PUFA being more effective than MUFA [19% reduction versus 11%].

The investigators found per 5% of energy (5 En%) replacement of saturated fat with polyunsaturated fatty acid and fish oil significantly lowered risk of cardiovascular mortality with 28%.  

The investigators found replacing saturated fat with PUFA or MUFA was equally effective at reducing coronary heart disease (CHD) events

The investigators found replacement of saturated fat with whole grains significantly lowered coronary heart disease events while replacement with sugar and starch significantly increased coronary heart disease events.

The investigators found replacement of saturated fat with carbohydrate had no effect on coronary heart disease events or death.

The investigators found only PUFA replacement of saturated fat significantly lowered coronary heart disease events and cardiovascular and total mortality.

The investigators concluded reducing saturated fat and replacing it with carbohydrate will not lower coronary heart disease events or cardiovascular mortality although it will reduce total mortality. Replacing saturated fat with PUFA, MUFA or high-quality carbohydrate will lower coronary heart disease events.

Original title:
A systematic review of the effect of dietary saturated and polyunsaturated fat on heart disease by Clifton PM and Keogh JB.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/29174025

Additional information of El Mondo:
Find more information/studies on fat, carbohydrates and cardiovascular diseases right here.

Objectives:
What are the cardiovascular benefits of indiscriminate supplementation of omega-3 supplementation?

Study design:
This review article included 8 RCTs.

Results and conclusions:
The investigators found omega-3 supplementation significantly resulted in a 8% decrease of the risk of cardiac death, unless the patients are treated by statins.

The investigators found omega-3 supplementation prolonged quality adjusted life years by about a month. Old people gained less, whereas diabetes mellitus type 2 patients and people with history of cardiovascular events gained more.

The investigators concluded omega-3 supplementation decreases risk of cardiac death, unless the patients are treated by statins.

Original title:
The cardiovascular benefits of indiscriminate supplementation of omega-3 fatty acids; meta-analysis and decision-making approach by Leshno M, Goldbourt U, [...], Lichtenberg D.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/29171335

Additional information of El Mondo:
Find more information/studies on omega-3 fatty acids and cardiovascular diseases right here.

Objectives:
Beetroot is considered a complementary treatment for hypertension because of its high content of inorganic NO3.

The aim of this meta-analysis (review article) is to clarify several aspects of beetroot juice supplementation on systolic blood pressure (SBP) and diastolic blood pressure (DBP).

Study design:
This review article included 22 RCTs with a total of 47 intervention (n = 650) and 43 control (n = 598) groups.

Results and conclusions:
The investigators found overall, systolic blood pressure [-3.55 mmHg, 95% CI = -4.55 to -2.54 mmHg] and diastolic blood pressure [-1.32 mmHg, 95% CI = -1.97 to -0.68 mmHg] were significantly lower in the beetroot juice-supplemented groups than in the control groups.

The investigators found the mean difference of systolic blood pressure was larger between beetroot juice-supplemented and control groups in the longer than in the shorter (≥14 compared with 14 days) study durations [-5.11 compared with -2.67 mmHg].

The investigators found the mean difference of systolic blood pressure was larger between beetroot juice-supplemented and control groups in the highest compared with the lowest (500 compared with 70 and 140 mL/d] doses of beetroot juice [-4.78 compared with -2.37 mmHg].

The investigators found a positive correlation between beetroot juice doses and the mean differences of blood pressures.

The investigators found a smaller effect size of blood pressures after supplementation with higher NO3 (milligrams per 100 mL beetroot juice).

The investigators found a weak effect size in a meta-analysis of trials that used NO3-depleted beetroot juice as a placebo compared with other interventions [-3.09 compared with -4.51 mmHg for systolic blood pressure and -0.81 compared with -2.01 mmHg for diastolic blood pressure].

The investigators concluded beetroot juice supplementation, particularly 500 mL/d beetroot juice during at least 14 days, reduces blood pressure.

Original title:
The Nitrate-Independent Blood Pressure-Lowering Effect of Beetroot Juice: A Systematic Review and Meta-Analysis by Bahadoran Z, Mirmiran P, […], Ghasemi A.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/29141968

Additional information of El Mondo:
Find more information/studies on fruit, hypertension prevention and cardiovascular diseases right here.

Objectives:
What is the relationship of the intake of whole grains, refined grains, vegetables, fruits, nuts, legumes, eggs, dairy, fish, red meat, processed meat and sugar-sweetened beverages (SSBs) and the risk of hypertension?

Study design:
This review article included 28 prospective cohort studies.

Results and conclusions:
The investigators found in dose-response meta-analysis of 4 studies with 28,069 incident hypertension cases, a significantly reduced risk of 8% [RR = 0.92, 95% CI = 0.87-0.98, I2 = 88%, p 0.0001] for hypertension for 30 g/day whole grains. Significant means that there is an association with a 95% confidence.
The reduced risk was highest (15%) at 90 g/day whole grains.

The investigators found in dose-response meta-analysis of 6 studies, a significantly reduced risk of 3% [RR = 0.97, 95% CI = 0.96-0.99, I2 = 64%, p = 0.02] for hypertension for 100 g/day fruits.
The strongest risk reduction was 7% at 300 g/day fruits.

The investigators found in dose-response meta-analysis of 9 studies with 31,509 incident hypertension cases, a significantly reduced risk of 5% [RR = 0.95, 95% CI = 0.94-0.97, I2 = 0%, p = 0.50] for hypertension for 200 g/day dairy products.
The strongest risk reduction was 15% at 800 g/day dairy products.

The investigators found in dose-response meta-analysis of 7 studies with 97,745 incident hypertension cases, a significantly increased risk of 14% [RR = 1.14, 95% CI = 1.02-1.28, I2 = 88%, p 0.001] for hypertension for 100 g/day red meat.
The increased risk was highest (40%) at 200 g/day red meat.

The investigators found in dose-response meta-analysis of 4 studies, a significantly increased risk of 12% [RR = 1.12, 95% CI = 1.00-1.26, I2 = 82%, p 0.001] for hypertension for 50 g/day processed meat.

The investigators found in dose-response meta-analysis of 4 studies, a significantly increased risk of 7% [RR = 1.07, 95% CI = 1.04-1.10, I2 = 64%, p = 0.04] for hypertension for 250 mL/day sugar-sweetened beverages.
The increased risk was highest (13%) at 450 mL/day sugar-sweetened beverages.

The investigators found compared with nonconsumption, an intake of 2 servings red meat/d [170g, RR = 1.35], 1 serving processed meat/d [35g, RR = 1.07], 1 serving fish/d [100g, RR = 1.08] and 2 servings sugar-sweetened beverages/d [500mL, RR = 1.14 was associated with a 78% increased risk of hypertension. On the other hand, a risk reduction by 44% would be achieved by not consuming these foods (red meat, processed meat, fish and sugar-sweetened beverages).

The investigators concluded a daily dietary intake of 30g whole grains, 100g fruits, 200g dairy products reduce risk of hypertension, whereas a daily dietary intake of 100g red meat, 50g processed meat, and 250mL sugar-sweetened beverages increase risk of hypertension. These findings need to be seen under the light of very-low to low credibility of meta-evidence. However, the findings support the current dietary recommendations in the primary prevention of hypertension.

Original title:
Food Groups and Risk of Hypertension: A Systematic Review and Dose-Response Meta-Analysis of Prospective Studies by Schwingshackl L, Schwedhelm C, […], Boeing H.

Link:
http://advances.nutrition.org/content/8/6/793.long

Additional information of El Mondo:
Find more information/studies on different food groups, hypertension prevention and cardiovascular diseases right here.

Objectives:
Previous meta‐analyses on meat intake and risk of stroke did not report the effect of white meat (poultry meat, excluding fish) and did not examine stroke incidence and mortality separately. Therefore, this review article (meta-analysis) has been conducted.

What is the relationship of total (red and processed meat), red (unprocessed or fresh red meat) and processed (processed red meat) meat consumption along with white meat on risk of stroke incidence and mortality disease risk?

Study design:
This review article included 15 prospective cohort studies (254,742 participants with 9,522 stroke incidents and 487,150 participants with 12,999 cases of stroke mortality). The follow-up duration varied from 5.5 to 26 years.

There was no significant publication bias based on the Egger test except that the evaluation of total meat with stroke incidence reached the significance threshold.

The average score for study quality assessed by the Newcastle‐Ottawa Scale was 7.29 (range 7-8) for studies on meat consumption and stroke incidence and 6.87 (range 6-8) for those on stroke mortality.

Results and conclusions:
The investigators found that a high total meat (red and processed meat) consumption resulted in a significantly higher risk of 18% [pooled relative risk = 1.18, 95% CI = 1.09-1.28, I2 = 0%] for total stroke incidence. Significantly means that there is an association with a 95% confidence.

The investigators found that a high red meat consumption resulted in a significantly higher risk of 11% [pooled relative risk = 1.11, 95% CI = 1.03-1.20, I2 = 0%] for total stroke incidence.

The investigators found that a high processed meat consumption resulted in a significantly higher risk of 17% [pooled relative risk = 1.17, 95% CI = 1.08-1.25, I2 = 0%] for total stroke incidence.

The investigators found that a high white meat consumption resulted in a significantly lower risk of 13% [pooled relative risk = 0.87, 95% CI = 0.78-0.97, I2 = 0%] for total stroke incidence.

The investigators found, however, no significant associations between consumption of total [RR = 0.97, 95% CI = 0.85-1.11, I2 = 0%] or red meat [RR = 0.87, 95% CI = 0.64-1.18, I2 = 70.9%] and stroke mortality. No significant associations because RR of 1 was found in the 95% CI of 0.64 to 1.18. RR of 1 means no risk/association.

The investigators found that a high total meat consumption was associated with an increased risk of 41% for hemorrhagic stroke [RR = 1.41, 95% CI = 1.08-1.84, I2 = 0%], but no significant association was found between a high total meat consumption and ischemic stroke [RR = 1.16, 95% CI = 0.94-1.43, I2 = 40.6%].

The investigators found a positive association between total meat consumption and stroke incidence, regardless of sex, number of cases and follow‐up duration.

The investigators found when stratified by adjustment variables, studies that adjusted for family history of myocardial infarction, fruit and vegetable intake and use of aspirin showed a statistically significant relationship between total meat intake and risk of stroke compared with other studies that did not include those as adjustment variables.

The investigators found that a high red meat consumption was associated with an increased risk of 24% for ischemic stroke [RR = 1.24, 95% CI = 1.05-1.46, I2 = 17.7%], but no significant association was found between a high red meat consumption and hemorrhagic stroke [RR = 1.11, 95% CI = 0.89-1.38, I2 = 0%].

The investigators found that a high processed meat consumption was linked to neither ischemic [RR = 1.10, 95% CI = 0.96-1.27, I2 = 11.4%] nor hemorrhagic stroke [RR = 1.19, 95% CI = 0.95-1.49, I2 = 8.10%].

The investigators concluded that higher consumption of red or processed meat is associated with an increase in the risk of stroke, while higher intake of white meat is related to a reduction in stroke incidence. Therefore, recommendations for replacing proportions of red and processed meat to white meat for the prevention of stroke may be considered in clinical practice.

Original title:
Role of Total, Red, Processed, and White Meat Consumption in Stroke Incidence and Mortality: A Systematic Review and Meta-Analysis of Prospective Cohort Studies by Kim K, Hyeon J, […], Park SM.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634267/

Additional information of El Mondo:
Find more information/studies on meat consumption and cardiovascular diseases right here.

Objectives:
Dietary fiber intake, especially viscous soluble fiber, has been established as a means to reduce cardiometabolic risk factors. Whether this is true for blood pressure remains controversial. Therefore, this review article (meta-analysis) has been conducted.

Does viscous soluble fiber supplementation reduce cardiovascular disease risk?

Study design:
This review article included 22 (n = 1430) and 21 RCTs (N = 1343) for systolic blood pressure (SBP) and diastolic blood pressure (DBP), respectively.

5 types of viscous fiber supplementation were β-glucan from oats and barley, guar gum, konjac, pectin and psyllium.

Results and conclusions:
The investigators found viscous soluble fiber supplementation significantly reduced systolic blood pressure [MD = -1.59 mmHg, 95% CI = -2.72 to -0.46, I2 = 72%, p 0.01] and diastolic blood pressure [MD = -0.39 mmHg, 95% CI = -0.76 to -0.01, I2 = 67%, p 0.01] at a median dose of 8.7 g/day (1.45-30 g/day) over a median follow-up of 7-weeks.

The investigators found within the five fiber types, systolic blood pressure reductions were observed only for supplementation using psyllium fiber [MD = -2.39 mmHg, 95% CI = -4.62 to -0.17].

The investigators concluded 8.7 g/day viscous soluble fiber supplementation, particularly psyllium fiber during 7 weeks reduces systolic blood pressure (SBP) and diastolic blood pressure (DBP). Therefore, inclusion of viscous fiber to habitual diets may have additional value in reducing cardiovascular risk via improvement in blood pressure.

Original title:
The effect of viscous soluble fiber on blood pressure: A systematic review and meta-analysis of randomized controlled trials by Khan K, Jovanovski E, […], Vuksan V.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/29153856

Additional information of El Mondo:
Find more information/studies on fiber consumption, hypertension and cardiovascular diseases right here.

Objectives:
Elevated cholesterol has been linked to cardiovascular disease in adults and preclinical markers of atherosclerosis in children, thus reducing saturated (SFA) and trans-fatty acids (TFA) intake from an early age may help to reduce cholesterol and the risk of cardiovascular disease later in life. The World Health Organization (WHO) is currently updating its guidance on SFA and TFA intake in adults and children. Therefore, this review article (meta-analysis) has been conducted.

Does a diet with low saturated fatty acids reduce cholesterol and blood pressure in children and adolescents between 2 to 19 years of age?

Study design:
This review article included 8 RCTs (5 trials had a duration of 1 year and 3 had a duration of ≥ 1year with a total of 2,430 individual children and adolescents between 2 to 19 years of age) and 3 cohort studies.

Minimum duration was 13 days for RCTs and one year for cohort studies.

Saturated fatty acids intake was assessed using 24hr dietary recalls in 4 trials, 3-day diet records in 3 trials and food frequency questionnaires and/or checklists in 2 trials.

No trials were identified meeting the inclusion criteria for trans-fatty acids.

Publication bias was not assessed as the number of trials found was not sufficient to conduct funnel plot analyses for any outcome measure.

Results and conclusions:
The investigators found compared with control diets, there was a highly statistically significant effect of reduced saturated fatty acids intake on total cholesterol [MD = -0.16 mmol/L, 95% CI = -0.25 to -0.07, I2 = 64%], LDL cholesterol [MD = -0.13 mmol/L, 95% CI = -0.22 to -0.03, I2 = 77%] and diastolic blood pressure [MD = -1.45 mmol/L, 95% CI = -2.34 to -0.56].
The effects on cholesterol were greatest among those in which saturated fatty acids was replaced primarily with PUFA or MUFA and when the intervention group achieved a reduction in saturated fatty acids to below 10% of total energy intake.

The investigators found subgroup analysis of the effect of the initial lipid status of the participants showed a significantly different effect of saturated fatty acids reduction on total cholesterol [p = 0.05] between trials involving normolipidaemic/mixed status children [MD -0.21 mmol/L, 95% CI = -0.31 to -0.12] vs hyperlipidaemic children [MD = -0.08 mmol/L, 95% CI = -0.15 to -0.01].

The investigators found subgroup analysis of the effect of the initial lipid status of the participants showed the reduction in LDL cholesterol (bad cholesterol) was greater among the trials conducted in normolipidaemic/mixed status [MD -0.21 mmol/L, 95% CI = -0.30 to -0.13] vs hyperlipidaemic children [MD = -0.02 mmol/L, 95% CI = -0.14 to -0.11].

The investigators found there were no significant associations observed for HDL cholesterol (good cholesterol), triglycerides or apolipoproteins A1 or B.

The investigators found there were no significant associations observed between reduced saturated fatty acids intake and weight, height, body mass index (BMI) or waist circumference.

The investigators found there was no evidence of adverse effects of reducing saturated fatty acids intake in children on micronutrient intakes, cognitive development or sexual maturation in the small number of trials reporting these outcomes.  

The investigators concluded a diet with low saturated fatty acids reduces total cholesterol, LDL cholesterol and diastolic blood pressure in children and adolescents between 2 to 19 years of age without evidence of adverse effects on growth and development. The greatest effect on cholesterol occurred when saturated fatty acids was replaced with PUFA or a mixture of PUFA/MUFA and when saturated fatty acids intake was less than 10% of total energy intake. Therefore, dietary guidelines for children and adolescents should continue to recommend diets low in saturated fat.

Original title:
Health effects of saturated and trans-fatty acid intake in children and adolescents: Systematic review and meta-analysis by Morenga L and Montez JM.

Link:
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0186672

Additional information of El Mondo:
Find more information/studies on fat consumption, body mass index, hypertension, cholesterol and cardiovascular diseases right here.  

A diet with saturated fatty acids intake less than 10% of total energy intake is a diet with less than 10 En% saturated fat.
A diet with less than 10 En% saturated fat is a diet that is largely made up of meals/products with less than 10 En% saturated fat. Practically, this means that all meals/products that you eat on a daily basis should on average contain less than 10 En% saturated fat. Check here which products contain less than 10 En% saturated fat.

Objectives:
Despite growing evidence for food-based dietary patterns' potential to reduce cardiovascular disease risk, knowledge about the amounts of food associated with the greatest change in risk of specific cardiovascular outcomes and about the quality of meta-evidence is limited. Therefore, this review article (meta-analysis) has been conducted.

Which food-based dietary patterns reduce risk of cardiovascular diseases, such as coronary heart disease (CHD), stroke and heart failure (HF)?

Study design:
This review article included 123 prospective cohort studies.

Results and conclusions:
The investigators found whole grains significantly reduced risk of coronary heart disease with 5% [RR = 0.95, 95% CI = 0.92-0.98]. Significantly means that there is an association with a 95% confidence.

The investigators found whole grains significantly reduced risk of heart failure with 4% [RR = 0.96, 95% CI = 0.95-0.97]. Significantly because RR of 1 was not found in the 95% CI of 0.95 to 0.97. RR of 1 means no risk/association.

The investigators found vegetables significantly reduced risk of coronary heart disease with 3% [RR = 0.97, 95% CI = 0.96-0.99]. Significantly means it can be said with a 95% confidence that a intake of vegetables really decreased the risk of getting coronary heart disease with 3%.  

The investigators found fruits significantly reduced risk of coronary heart disease with 6% [RR = 0.94, 95% CI = 0.90-0.97].

The investigators found vegetables significantly reduced risk of stroke with 8% [RR = 0.92, 95% CI = 0.86-0.98].

The investigators found fruits significantly reduced risk of stroke with 10% [RR = 0.90, 95% CI = 0.84-0.97].

The investigators found nuts non-significantly reduced risk of coronary heart disease with 33% [RR = 0.67, 95% CI = 0.43-1.05]. Non-significantly means that there is no association with a 95% confidence.

The investigators found fish consumption significantly reduced risk of stroke with 14% [RR = 0.86, 95% CI = 0.75-0.99].

The investigators found fish consumption significantly reduced risk of heart failure with 20% [RR = 0.80, 95% CI = 0.67-0.95].

The investigators found egg significantly increased risk of heart failure with 16% [RR = 1.16, 95% CI = 1.03-1.31].

The investigators found red meat significantly increased risk of coronary heart disease with 15% [RR = 1.15, 95% CI = 1.08-1.23].

The investigators found red meat significantly increased risk of stroke with 12% [RR = 1.12, 95% CI = 1.06-1.17].

The investigators found red meat significantly increased risk of heart failure with 8% [RR = 1.08, 95% CI = 1.02-1.14].

The investigators found processed meat significantly increased risk of coronary heart disease with 27% [RR = 1.27, 95% CI = 1.09-1.49].

The investigators found processed meat significantly increased risk of stroke with 17% [RR = 1.17, 95% CI = 1.02-1.34].

The investigators found processed meat significantly increased risk of heart failure with 12% [RR = 1.12, 95% CI = 1.05-1.19].

The investigators found sugar-sweetened beverages significantly increased risk of coronary heart disease with 17% [RR = 1.17, 95% CI = 1.11-1.23].

The investigators found sugar-sweetened beverages significantly increased risk of heart failure with 7% [RR = 1.07, 95% CI = 1.02-1.12].

The investigators found sugar-sweetened beverages significantly increased risk of stroke with 8% [RR = 1.08, 95% CI = 1.05-1.12].

The investigators found there were clear indications for non-linear dose-response relationships between whole grains, fruit, nuts, dairy and red meat and coronary heart disease.

The investigators concluded there is a relationship between food-based dietary patterns and risk of cardiovascular diseases, with an increased risk for consumption of eggs, red meat, processed meat and sugar-sweetened beverages and a decreased risk for consumption of whole grains, vegetables, fruit and fish.

Original title:
Food groups and risk of coronary heart disease, stroke and heart failure: A systematic review and dose-response meta-analysis of prospective studies by Bechthold A, Boeing H, […], Schwingshackl L.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/29039970

Additional information of El Mondo:
Find more information/studies on food groups and cardiovascular diseases right here. 

Objectives:
The therapeutic efficacy of coenzyme Q10 on patients with cardiac failure remains controversial. Therefore, this review article (meta-analysis) has been conducted.

Do patients with heart failure benefit from coenzyme Q10 supplements?

Study design:
This review article included a total of 14 RCTs with 1064 patients in coenzyme Q10 (treatment) group and 1085 patients in placebo (control) group.

Egger’s test results showed no significant evidence of publication bias in either endpoint.

Results and conclusions:
The investigators found compared with placebo, coenzyme Q10 supplementation significantly decreased mortality risk with 31% [RR = 0.69, 95% CI = 0.50 to 0.95, p = 0.02, I2 = 0%].

The investigators found a greater improvement in exercise capacity was established in patients who used coenzyme Q10 than in those who used placebo [SMD = 0.62, 95% CI = 0.02 to 0.30, p = 0.04, I2 = 54%].

The investigators found patients who used coenzyme Q10 and placebo associated with similar left heart ejection fraction [SMD = 0.14, 95% CI = -0.08 to 0.37, p = 0.22, I2 = 54%].

The investigators found no significant difference between coenzyme Q10 and placebo for NYHA classification [SMD = -0.70, 95% CI = -1.92 to 0.51, p = 0.26, I2 = 89%].

The investigators concluded in patients with heart failure, the administration of coenzyme Q10 results in lower mortality and improved exercise capacity compared with the effects of placebo treatment.

Original title:
Efficacy of coenzyme Q10 in patients with cardiac failure: a meta-analysis of clinical trials by Lei L and Liu Y.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525208/

Additional information of El Mondo:
Find more information/studies on coenzyme Q10 and cardiovascular diseases right here. 

Objectives:
Several previous meta-analyses show a consistent inverse association between nut consumption and all-cause mortality, but the associations with cause-specific mortality remain uncertain. Therefore, this meta-analysis (review article) has been conducted.

Does nut consumption reduce all-cause and cause-specific mortality?

Study design:
This review article included 18 prospective cohort studies with 81,034 deaths.

Results and conclusions:
The investigators found random-effects meta-analysis of 18 studies with 81,034 deaths showed a significant reduced risk of 19% [summary RR = 0.81, 95% CI = 0.78-0.84] for all-cause mortality for high compared with low nut consumption. This significant reduced risk was broadly consistent within subgroups according to various study and population characteristics and within sensitivity analyses that took into account potential confounders.

The investigators found random-effects meta-analysis of 17 studies with 20,381 deaths showed a significant reduced risk of 25% [summary RR = 0.75, 95% CI = 0.71-0.79] for cardiovascular mortality for high compared with low nut consumption. This significant reduced risk was broadly consistent within subgroups according to various study and population characteristics and within sensitivity analyses that took into account potential confounders.

The investigators found random-effects meta-analysis of 14 studies with 10,438 deaths showed a significant reduced risk of 27% [summary RR = 0.73, 95% CI = 0.67-0.80] for coronary heart disease mortality for high compared with low nut consumption. This significant reduced risk was broadly consistent within subgroups according to various study and population characteristics and within sensitivity analyses that took into account potential confounders.

The investigators found random-effects meta-analysis of 13 studies with 4,850 deaths showed a significant reduced risk of 18% [summary RR = 0.82, 95% CI = 0.73-0.91] for stroke mortality for high compared with low nut consumption. This significant reduced risk was broadly consistent within subgroups according to various study and population characteristics and within sensitivity analyses that took into account potential confounders.

The investigators found random-effects meta-analysis of 11 studies with 21,353 deaths showed a significant reduced risk of 13% [summary RR = 0.87, 95% CI = 0.80-0.93] for cancer mortality for high compared with low nut consumption. This significant reduced risk was broadly consistent within subgroups according to various study and population characteristics and within sensitivity analyses that took into account potential confounders.

The investigators found peanut (5 studies) and tree nut (3 studies) consumption were similarly associated with mortality risks.

The investigators found dose-response analyses suggested evidence for nonlinear associations between nut consumption and mortality [p-nonlinearity 0.001 for all outcomes except cancer mortality], with mortality risk levelling off at the consumption of about 3 servings per week (12g/day).

The investigators concluded that nut consumption is associated with reduced all-cause and cause-specific mortality, with the strongest reduction for coronary heart disease (CHD) mortality. Both tree nuts and peanuts lower mortality and most of the survival benefits could be achieved at a relative low level of nut consumption (up to 12g/day).

Original title:
Nut consumption in relation to all-cause and cause-specific mortality: a meta-analysis 18 prospective studies by Chen GC, Zhang R, [...], Qin LQ.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/28875220

Additional information of El Mondo:
Find more information/studies on nut consumption, cancer, cardiovascular disease and stroke right here.
 

Objectives:
Anthocyanins are of interest due to their anti-oxidative and vasodilatory properties. Earlier reviews have shown that berries and other anthocyanin rich foods or extracts can improve vascular health. However, the effect of anthocyanins on vascular function has not yet been reviewed. Therefore, this review article (meta-analysis) has been conducted.

Does anthocyanin supplementation improve vascular function?

Study design:
This review article included 29 RCTs (15 were parallel and 14 were crossover designs).
Anthocyanin intakes ranged from 1 to 724 mg/day.
Most studies (n = 19) involved participants in the middle to older age group (mean age ≥ 40 years).
The number of participants that completed each study ranged from 10 to 146.
Intervention durations ranged from 1 h to 6 h in the acute studies and one week to six months in the chronic studies.

There was no publication bias.

Results and conclusions:
The investigators found compared to placebo-control, acute anthocyanin supplementation (1-8 h post consumption of anthocyanin doses between 7 and 724 mg) significantly improved FMD [SMD = 3.92%, 95% CI = 1.47 to 6.38, p = 0.002, I2 = 91.8%].
No improvements were observed in PAT-RHI [SMD = 0.08, 95% CI = -0.34 to 0.50, p = 0.71, I2 = 0%].
Collectively, (i.e., the pooling of studies using FMD and/or PAT-RHI) anthocyanins may improve vascular reactivity [overall SMD = 2.41, 95% CI = 0.91 to 3.91, p = 0.002, I2 = 92.6%].

The investigators found compared to placebo-control, acute anthocyanin supplementation (1-8 h post consumption of anthocyanin doses between 7 and 724 mg) also significantly improved arterial stiffness, using PWV [SMD = -1.27 m/s, 95% CI = -1.96 to -0.58, p = 0.000, I2 = 17.9%].

The investigators found pulse wave velocity was improved following acute anthocyanin supplementation only [SMD = -1.27 m/s, 95% CI = -1.96 to -0.58, p = 0.000, I2 = 17.8%]. 

The investigators found compared to placebo-control, chronic anthocyanin supplementation (one week to six months and used anthocyanin doses of 12 to 320 mg/day) significantly improved FMD [SMD = 0.84%, 95% CI = 0.55 to 1.12, p = 0.000, I2 = 62.5%].
Collectively (i.e., the pooling of studies using FMD and/or PAT-RHI), chronic anthocyanin supplementation may improve vascular reactivity [overall SMD = 0.77, 95% CI = 0.37 to 1.16, p = 0.000, I2 = 85.3%].

The investigators concluded that both acute and chronic anthocyanin supplementation improve vascular health, particularly with respect to vascular reactivity measured by FMD. However, more research is required to determine the optimal dosage and the long-term effects of anthocyanin consumption.

Original title:
The Effect of Anthocyanin-Rich Foods or Extracts on Vascular Function in Adults: A Systematic Review and Meta-Analysis of Randomised Controlled Trials by Fairlie-Jones L, Davison K, […], Hill AM.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579701/

Additional information of El Mondo:
Find more information/studies on flavonoids and cardiovascular diseases right here.  

Objectives:
Although epidemiological studies have examined the role of chocolate in preventing cardiometabolic disease, the results remain inconsistent. Therefore, this review article (meta-analysis) has been conducted.

Does chocolate consumption reduce risk of coronary heart disease (CHD), stroke and diabetes?

Study design:
This review article included 14 prospective cohort studies, with 508,705 participants from six countries and 7,267 coronary heart disease (CHD) cases, 8,197 stroke cases and 13,271 diabetes cases.
The follow-up duration of the studies ranged from 5 to 16 years.
One serving was defined as 30g of chocolate.
The majority of chocolate consumed in the included studies was milk or dark chocolate.

Results and conclusions:
The investigators found in 6 cohort studies for the highest versus lowest intake of chocolate a significant reduced risk of 10% for coronary heart disease [pooled RR = 0.90, 95% CI = 0.82-0.97, I2 = 24.3%, p = 0.25]. Leave-one-out sensitivity analysis had no significant influence on the pooled results.

The investigators found regarding CHD subtype, a significant reduced risk of 14% [RR = 0.86, 95% CI = 0.77-0.96] for myocardial infarction.

The investigators found for studies with follow-up duration of 10 years a significant reduced risk of 28% for coronary heart disease [RR = 0.72, 95% CI = 0.57-0.92].

The investigators found for studies with follow-up duration of ≥10 years a significant reduced risk of 8% for coronary heart disease [RR = 0.92, 95% CI = 0.86-0.99].

The investigators found in dose-response meta-analysis of 5 studies a curvilinear association between chocolate consumption and risk of coronary heart disease [p for nonlinearity = 0.006].

The investigators found in dose-response meta-analysis, compared with no intake, a significant reduced risk of 6% for coronary heart disease for 1 serving (30g) chocolate per week [RR = 0.94, 95 CI = 0.90-0.99].   

The investigators found in dose-response meta-analysis, compared with no intake, a significant reduced risk of 9% for coronary heart disease for 3 servings (90g) chocolate per week [RR = 0.91, 95 CI = 0.85-0.97].   

The investigators found in dose-response meta-analysis, compared with no intake, a significant reduced risk of 11% for coronary heart disease for 7 servings (210g) chocolate per week [RR = 0.89, 95 CI = 0.83-0.95].   

The investigators found in dose-response meta-analysis, compared with no intake, a significant reduced risk of 12% for coronary heart disease for 10 servings (300g) chocolate per week [RR = 0.88, 95 CI = 0.81-0.95].   

The investigators found in 8 reports from 7 studies for the highest versus lowest level of chocolate consumption a significant reduced risk of 16% for stroke [pooled RR = 0.84, 95% CI = 0.78-0.90, I2 = 0%, p = 0.49]. The pooled risk of total stroke was not obviously modified in the sensitivity analysis by excluding one study at a time
Egger’s test suggested the presence of publication bias [p = 0.008]. However, after introducing the “trim and fill” method to adjust this bias, the overall risk estimate remained significant in favor of chocolate intake [RR = 0.86, 95% CI = 0.79-0.92].

The investigators found with regard to stroke subtypes, a significant reduced risk of 13% [RR = 0.87, 95% CI = 0.78-0.96] for cerebral infarction and a significant reduced risk of 17% [RR = 0.83, 95% CI = 0.71-0.97] for hemorrhagic stroke.

The investigators found in the stratified analysis by gender, a significant reduced risk of 13% of total stroke for male [RR = 0.87, 95% CI = 0.79-0.97] and a significant reduced risk of 16% of total stroke for female [RR = 0.84, 95% CI = 0.74-0.94].

The investigators found a significant reduced risk of 44% for studies with follow-up durations of 10 years [RR = 0.56, 95% CI = 0.37-0.85].

The investigators found a significant reduced risk of 15% for studies with follow-up durations of ≥10 years [RR = 0.85, 95% CI = 0.79-0.91].

The investigators found in 7 reports from 6 studies a nonlinear correlation between chocolate intake and risk of stroke [p for nonlinearity = 0.001].

The investigators found in dose-response meta-analysis, compared with no intake, a significant reduced risk of 9% for stroke for 1 serving chocolate per week [RR = 0.91, 95% CI = 0.86-0.97].   

The investigators found in dose-response meta-analysis, compared with no intake, a significant reduced risk of 13% for stroke for 3 servings chocolate per week [RR = 0.87, 95% CI = 0.81-0.94].   

The investigators found in dose-response meta-analysis, compared with no intake, a significant reduced risk of 15% for stroke for 7 servings chocolate per week [RR = 0.85, 95% CI = 0.76-0.93].   

The investigators found in dose-response meta-analysis, compared with no intake, a significant reduced risk of 17% for stroke for 10 servings chocolate per week [RR = 0.83, 95% CI = 0.72-0.94].   

The investigators found in 4 studies using “trim and fill” method, for the highest versus lowest intake of chocolate, a non-significant reduced risk of 8% for diabetes [pooled RR = 0.92, 95% CI = 0.78-1.08].

The investigators found in stratified analysis by sex, a significant reduced risk of 21% [RR = 0.79, 95% CI = 0.65-0.96] for men and a non-significant reduced risk of 8% [RR = 0.92, 95% CI = 0.72-1.17] for women.
Similarly, the risks of diabetes were not different between subsets of studies with follow-up durations of below or over 10 years [p for interaction = 0.51].

The investigators found in dose-response meta-analysis of 6 reports, a curvilinear association between chocolate intake and risk of diabetes [p for nonlinearity 0.001].

The investigators found in dose-response meta-analysis, compared with no intake, a significant reduced risk of 20% for diabetes for 1 serving chocolate per week [RR = 0.80, 95% CI = 0.71-0.91]. Significant means that there is an association with a 95% confidence.

The investigators found in dose-response meta-analysis, compared with no intake, a significant reduced risk of 24% for diabetes for 3 servings chocolate per week [RR = 0.76, 95% CI = 0.63-0.91]. Significant because RR of 1 was not found in the 95% CI of 0.63 to 0.91. RR of 1 means no risk/association.

The investigators found in dose-response meta-analysis, compared with no intake, a non-significant reduced risk of 17% for diabetes for 7 servings chocolate per week [RR = 0.83, 95% CI = 0.67-1.03]. Non-significant means it cannot be said with a 95% confidence that 7 servings chocolate per week really decreased the risk of diabetes with 17%.

The investigators found in dose-response meta-analysis, compared with no intake, a non-significant reduced risk of 11% for diabetes for 10 servings chocolate per week [RR = 0.89, 95% CI = 0.69-1.16].   

The investigators found in general, the dose-response pattern was J-shaped and the peak reduction in diabetes risk occurred at an intake of 2 servings/week [RR = 0.75, 95% CI = 0.63-0.89], with no protective effects observed when consuming chocolate > 6 servings/week.

The investigators concluded that chocolate consumption confers reduced risks of coronary heart disease, stroke and diabetes. Consuming chocolate in moderation (1-6 servings/week or 30-180g) may be optimal for the prevention of these burdensome diseases. However, additional large prospective studies are required to confirm the observed benefits of chocolate in populations with different characteristics and to establish the optimum frequency of chocolate intake for preventing cardiometabolic disease.

Original title:
Chocolate Consumption and Risk of Coronary Heart Disease, Stroke, and Diabetes: A Meta-Analysis of Prospective Studies by Yuan S, Li X, […], Lu J.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537803/

Additional information of El Mondo:
Find more information/studies on chocolate, diabetes and cardiovascular diseases right here.

Objectives:
The clinical benefits of perioperative antioxidant vitamin therapy in cardiac patients remain controversial. Therefore, this review article (meta-analysis) has been conducted.

Do patients undergoing cardiac surgery benefit from perioperative antioxidant vitamin therapy?

Study design:
This review article included 12 RCTs with 1584 cardiac patients.

Results and conclusions:
The investigators found compared with placebo or no antioxidant vitamin therapy that administration of antioxidant vitamin therapy resulted in a significant reduction:
-in postoperative atrial fibrillation (POAF) [RR = 0.55, 95% CI = 0.42 to 0.73, p  0.0001];
-duration of hospital stay [MD = -0.68, 95% CI = -0.98 to -0.39, p  0.00001];
-intensive care unit length of stay [MD = -0.21, 95% CI = -0.30 to -0.12, p  0.00001] and;      
-intubation time [MD = -2.41, 95% CI = -3.83 to -0.98, p = 0.001].

The investigators also found a trend towards a decrease in postoperative complications [RR = 0.72, 95% CI = 0.48-1.08, p = 0.11] and duration of postoperative atrial fibrillation [MD = -1.950, 95% CI = -3.28 to 0.29, p = 0.10].

The investigators concluded that perioperative antioxidant vitamin therapy in patients undergoing cardiac surgery reduces the incidence of postoperative atrial fibrillation, duration of hospital stay, intensive care unit length of stay and intubation time.

Original title:
The clinical benefits of perioperative antioxidant vitamin therapy in patients undergoing cardiac surgery: a meta-analysis by Geng J, Qian J, […], Shen Z.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/28645181

Additional information of El Mondo:
Find more information/studies on antioxidant and cardiovascular diseases right here.

Objectives:
Studies implicate choline and betaine metabolite trimethylamine N-oxide (TMAO) in cardiovascular disease (CVD). Therefore, this review article (meta-analysis) has been conducted.

Is there an association between choline and betaine dietary intake and cardiovascular disease?

Study design:
This review article included a total of 6 prospective cohort studies comprising 18,076 incident cardiovascular disease events, 5,343 cardiovascular disease deaths among 184,010 participants.

There was no evidence for heterogeneity among studies.
Only 2 studies provided data on phosphatidylcholine and cardiovascular disease mortality.

Results and conclusions:
The investigators found in random effects meta-analysis, incident cardiovascular disease was not associated with choline [RR = 1.00, 95% CI = 0.98-1.02] or betaine [RR = 0.99, 95% CI = 0.98-1.01] dietary intake.
Results did not vary by study outcome (incident coronary heart disease, stroke, total cardiovascular disease).

The investigators found random effects meta-analysis did not support an association between choline and cardiovascular disease mortality [RR = 1.09, 95% CI = 0.89-1.35], but one study supported a positive association and there was significant heterogeneity [I2 = 84%, p 0.001].

The investigators concluded that there is no association between dietary choline/betaine intake with incident cardiovascular disease, but further research into choline and cardiovascular disease mortality are needed.

Original title:
Dietary Choline and Betaine and Risk of CVD: A Systematic Review and Meta-Analysis of Prospective Studies by Meyer KA and Shea JW.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/28686188

Additional information of El Mondo:
Find more information/studies on choline and cardiovascular diseases right here.